Final Results from a Phase 2b Randomized, Placebo-Controlled Clinical Trial of RBX2660: A Microbiota-Based Drug for the Prevention of Recurrent Clostridioides difficile Infection

Abstract Introduction Effective treatments for recurrent Clostridioides difficile infection (rCDI) are urgently needed. RBX2660 is an investigational microbiota-based live biotherapeutic to reduce CDI recurrence following standard-of-care antibiotic treatment in individuals with rCDI. Here we report...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Erik R. Dubberke, Robert Orenstein, Sahil Khanna, Beth Guthmueller, Christine Lee
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Adis, Springer Healthcare 2022-12-01
Sarja:	Infectious Diseases and Therapy
Aiheet:	Live biotherapeutic product RBX2660 Clostridioides difficile Clostridium difficile Microbiota Recurrent CDI
Linkit:	https://doi.org/10.1007/s40121-022-00744-3
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!